We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$784M
Cap. Flow %
13.85%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.71%
2 Consumer Discretionary 8.71%
3 Technology 1.72%
4 Communication Services 0.79%
5 Real Estate 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLDO
126
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$4.05M 0.07%
500,500
– –
KA
127
DELISTED
Kineta, Inc. Common Stock
KA
$3.94M 0.07%
31,056
– –
KNTE
128
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.9M 0.07%
125,000
– –
SHLS icon
129
Shoals Technologies Group
SHLS
$1.33B
$3.48M 0.06%
+100,000
New +$3.54M
AXLA
130
DELISTED
Axcella Health Inc. Common Stock
AXLA
$3.39M 0.06%
28,500
– –
RNAM
131
DELISTED
Avidity Biosciences
RNAM
$3.11M 0.05%
142,500
– –
PARA
132
DELISTED
Paramount Global Class B
PARA
$3.04M 0.05%
+67,500
New +$4.12M
LVTX
133
DELISTED
LAVA Therapeutics
LVTX
$3.04M 0.05%
+200,000
New +$2.75M
CDAK
134
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$3.02M 0.05%
+200,000
New +$4.35M
KDNY
135
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.81M 0.05%
180,500
– –
LITS
136
Lite Strategy Inc
LITS
$32.4M
$2.61M 0.05%
38,000
– –
XLE icon
137
CALL
State Street Energy Select Sector SPDR ETF
XLE
$39B
$2.45M 0.04%
100,000
– –
ORIC icon
138
Oric Pharmaceuticals
ORIC
$1.17B
$2.45M 0.04%
100,000
– –
PTGX icon
139
Protagonist Therapeutics
PTGX
$8.55B
$1.94M 0.03%
75,000
-58,000
-44% -$1.47M
IRWD icon
140
Ironwood Pharmaceuticals
IRWD
$586M
$1.24M 0.02%
110,532
– –
CHMA
141
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.19M 0.02%
380,000
– –
RIGL icon
142
Rigel Pharmaceuticals
RIGL
$723M
$1.1M 0.02%
32,110
– –
SURF
143
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$780K 0.01%
100,000
– –
CDTX
144
DELISTED
Cidara Therapeutics
CDTX
$598K 0.01%
11,234
– –
CEREW
145
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$343K 0.01%
79,600
– –
MANU icon
146
Manchester United
MANU
$4.03B
$197K ﹤0.01%
+12,488
New +$211K
AAL icon
147
CALL
American Airlines Group
AAL
$9.82B
– –
-500,000
Closed -$7.88M
ABBV icon
148
CALL
AbbVie
ABBV
$465B
– –
-800,000
Closed -$85.7M
ACET icon
149
Adicet Bio
ACET
$77.6M
– –
-8,083
Closed -$1.82M
ADCT icon
150
ADC Therapeutics
ADCT
$140M
– –
-95,000
Closed -$3.04M
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.